SMS Pharmaceuticals has informed that pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Sec. 173 of the Companies Act, 2013 a meeting of the Board of Directors of the Company will be held on Saturday, the 28th day of July, 2018, at the Registered Office of the Company, to consider and approve the Unaudited Standalone Quarterly results for Quarter ended on 30th June, 2018. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and company’s Code for Regulation and Prohibition of Insider Trading Trading Window of the company shall remained closed for all the Directors / officers/ Designated Employees/ Promoters of the Company from, 21st July, 2018 to 30th June, 2018. Trading window will be open from 31st July, 2018.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: